Valuation Charles River Laboratories International, Inc. Deutsche Boerse AG
Stocks
RV6
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 204.10 EUR | -0.34% |
|
+1.64% | +18.77% |
| 30/07 | Align Technology to add directors, launch review after deal with Elliott | RE |
| 20/07 | Analyst recommendations: Global Payments, Charles Schwab, US Bancorp, Datadog, Netflix… |  |
Company Valuation: Charles River Laboratories International, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 18,941 | 11,138 | 12,252 | 9,520 | 10,023 | 11,199 | - | - |
| Change | - | -41.2% | 10% | -22.3% | 5.29% | 11.74% | - | - |
| Enterprise Value (EV) 1 | 21,366 | 13,616 | 14,622 | 11,565 | 11,946 | 13,013 | 12,585 | 12,203 |
| Change | - | -36.28% | 7.39% | -20.91% | 3.29% | 8.93% | -3.29% | -3.03% |
| P/E | 49.4x | 23.1x | 25.9x | 931x | -70x | 37.9x | 25.4x | 23.4x |
| PBR | 7.45x | 3.75x | 3.41x | 2.75x | 3.17x | 3.4x | 3.03x | 2.75x |
| PEG | - | 0.9x | -9.44x | -9.5x | 0x | -0x | 0.5x | 2.69x |
| Capitalization / Revenue | 5.35x | 2.8x | 2.97x | 2.35x | 2.5x | 2.91x | 2.86x | 2.73x |
| EV / Revenue | 6.04x | 3.42x | 3.54x | 2.86x | 2.98x | 3.38x | 3.21x | 2.98x |
| EV / EBITDA | 24.3x | 13.7x | 14.4x | 11.6x | 12.3x | 13.1x | 12x | 10.9x |
| EV / EBIT | 28.8x | 16.3x | 17.4x | 14.3x | 15x | 16x | 14.3x | 12.9x |
| EV / FCF | 40.2x | 46.2x | 40x | 23.1x | 23x | 25.3x | 20.3x | 38.8x |
| FCF Yield | 2.49% | 2.17% | 2.5% | 4.34% | 4.34% | 3.96% | 4.94% | 2.58% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 7.6 | 9.48 | 9.22 | 0.2 | -2.91 | 6.131 | 9.153 | 9.949 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 3,540 | 3,976 | 4,129 | 4,050 | 4,015 | 3,850 | 3,921 | 4,096 |
| EBITDA 1 | 879.5 | 990.9 | 1,013 | 996.1 | 971.5 | 990.4 | 1,053 | 1,120 |
| EBIT 1 | 742.1 | 834 | 838.8 | 805.9 | 793.9 | 811.4 | 882.4 | 947.5 |
| Net income 1 | 391 | 486.2 | 474.6 | 10.3 | -144.3 | 285.1 | 417.3 | 447 |
| Net Debt 1 | 2,425 | 2,477 | 2,370 | 2,046 | 1,923 | 1,814 | 1,385 | 1,004 |
| Reference price 2 | 375.34 | 218.92 | 238.84 | 186.16 | 203.66 | 232.51 | 232.51 | 232.51 |
| Nbr of stocks (in thousands) | 50,464 | 50,879 | 51,297 | 51,136 | 49,215 | 48,168 | - | - |
| Announcement Date | 16/2/22 | 22/2/23 | 14/2/24 | 19/2/25 | 18/2/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.83x | 5.9x | 17.55x | 0.98% | 48.53B | |
| -23.41x | 351.08x | -21.45x | -.--% | 39.87B | |
| 30.42x | 3.04x | 13.11x | -.--% | 38.68B | |
| 46.94x | 4.76x | 30.78x | -.--% | 35.13B | |
| 28.41x | 8.22x | 20.66x | 0.41% | 29.79B | |
| 32.82x | 5.37x | 24.39x | -.--% | 16.11B | |
| 22.67x | 1.99x | 8.61x | 1.17% | 13.61B | |
| 25.33x | 1.86x | 11.4x | -.--% | 12.62B | |
| Average | 24.50x | 47.78x | 13.13x | 0.32% | 29.29B | |
| Weighted average by Cap. | 23.42x | 63.80x | 12.18x | 0.32% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CRL Stock
- RV6 Stock
- Valuation Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
